Exabis Library
Welcome to the e-CCO Library!
P538: The reliability of patient performed fecal calprotectin testing
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P539: Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004–2007 and 2010–2013
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P539: Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P540: Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P540: Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel Diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P540: Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P540: The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus survey
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P540: Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P541 Are we addressing the top ten research priorities in IBD?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P541: Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P541: Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM